Neuren Pharmaceuticals (ASX:NEU) reported Friday 2024 earnings of AU$1.0861 per diluted share, down from AU$1.2012 a year earlier.
Analysts polled by Visible Alpha expected a diluted EPS of AU$0.95.
Revenue from ordinary activities for the year ended Dec. 31, 2024, was AU$227.8 million, down from AU$240.1 million a year earlier. Analysts surveyed by Visible Alpha expected AU$194.8 million.
Neuren anticipates earning royalties of AU$62 million to AU$67 million, assuming its global partner for trofinetide, Nasdaq-listed Acadia, meets its full-year net sales guidance of $380 million to $405 million for 2025, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.